Total medical devices industry venture financing deals in Q4 2020 worth $3.84bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 17.7% over the previous quarter and a drop of 2.8% when compared with the last four-quarter average, which stood at $4bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $2.31bn. At the country level, the US topped the list in terms of deal value at $2.3bn.

In terms of volumes, North America emerged as the top region for medical devices industry venture financing deals globally, followed by Asia-Pacific and then Europe.

The top country in terms of venture financing deals activity in Q4 2020 was the US with 123 deals, followed by China with 51 and Switzerland with 11.

In 2020, as of the end of Q4 2020, medical devices venture financing deals worth $16.43bn were announced globally, marking an increase of 49.6% year on year.

Medical devices industry venture financing deals in Q4 2020: Top deals

The top five medical devices industry venture financing deals accounted for 19% of the overall value during Q4 2020.

The combined value of the top five medical devices venture financing deals stood at $729m, against the overall value of $3.84bn recorded for the quarter.

The top five medical devices industry deals of Q4 2020 tracked by GlobalData were:

1) Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T Rowe Price Associates’ $200m venture financing of Tempus Labs

2) The $150m venture financing of Singlera Genomics by CICC Kai Tak Fund, DETONG Capital Partners, FutureX Skyline Capital, Huamei International, Linden Asset Management, Prosperico Ventures, Proxima Ventures, Shanghai Free Trade Zone Fund Tao Capital, Shanghai Furong Investment, Shenzhen Green Pine Capital Partners and Wuxi Financial Investment

3) CCB International Capital, China International Capital, China Renaissance Holdings, China Structural Reform Fund, CICC Capital ManagementLimited, GL Ventures, Matrix Partners China and Taikang Asset Management’s $149m venture financing of GeneCast Biotechnology

4) The $120m venture financing of Cytek Biosciences by Hillhouse Capital Group, LYFE Capital, Orbimed Advisors and RA Capital Management

5) ACE &SA, Alychlo, aMoon Partners, Credit Suisse Group, Endeavour Vision, Eurazeo Growth, Famille C Invest, Generation Investment Management, Hitachi Ventures, Pictet & Cie Group and Swisscom Ventures’ venture financing of Sophia Genetics for $110m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.